PTC secures FDA nod, Kronos Bio halts CDK9 development, Marinus slashes 45% of workforce amid setbacks [The good, the bad, the ugly]


Episode Artwork
1.0x
0% played 00:00 00:00
Nov 21 2024 3 mins   3

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:


The good — PTC secures FDA nod for brain-targeted gene therapy


The bad — Kronos Bio halts CDK9 development


The ugly — Marinus slashes 45% of workforce amid setbacks